Brawn Biotech Peer Comparison

BSE: 530207

₹23.95

₹0.95 (4.13%)

As on 28-Aug-2026 16:01IST

Market cap

₹7 Cr

Revenue (TTM)

₹17 Cr

P/E Ratio

8.4

P/B Ratio

1.6

Div. Yield

0 %

Edit

	Brawn Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Market cap (₹ Cr)	7	21,529	19,158	17,862	18,168
Revenue (₹ Cr)	17	2,570	2,287	2,432	3,230
Net Profit (₹ Cr)	0.86	735.15	678.07	169.62	666.92
Net Margin (%)	4.83	26.88	28.10	6.90	20.60
RoE (%)	21.33	19.16	19.73	20.76	18.75
Price to Earnings	8.38	29.29	28.79	105.31	28.22
Price-To-Book	1.60	4.88	5.09	19.75	4.49

Income Statement (₹ Cr)

	Brawn Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Operating Revenue	17.26	2,569.77	2,287.33	2,432.06	3,229.67
Total Income	17.76	2,735.39	2,413.29	2,458.54	3,237.12
Total Expenditure	17.72	1,628.14	1,490.75	2,202.20	2,090.06
EBITDA	-0.46	941.63	796.58	229.86	1,139.61
Depreciation	0.12	57.58	78.10	17.24	281.06
EBIT	-0.58	884.05	718.48	212.62	858.55
Interest	0.00	7.69	0.88	5.72	190.64
Other Income	0.50	165.62	125.96	26.48	7.45
Exceptional Items	0.00	-49.16	0.00	-5.13	-17.24
Profit before Tax	-0.08	992.82	843.56	228.25	658.12
Provision for Tax	-0.94	257.67	165.49	58.63	-8.80
Profit after Tax	0.86	735.15	678.07	169.62	666.92

	Brawn Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Shareholder's Funds	4.34	4,202.90	3,586.42	872.79	3,902.67
Minority Interest	0.00	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	1.35	91.50	28.74	134.50	1,392.75
Current Liabilities	15.17	627.48	385.94	981.81	2,077.10
Total Liabilities	20.49	4,911.11	3,207.85	1,879.19	6,862.28

	Brawn Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Non-Current Assets	1.82	770.28	1,291.22	42.47	5,617.77
Current Assets	17.12	3,803.22	2,585.66	1,739.93	1,539.85
Total Assets	20.49	4,911.11	3,207.85	1,879.19	6,862.28
Total Debt*	0.00	2.50	0.55	0.00	2,421.66
Net Current Assets	1.95	3,175.74	2,199.72	758.12	-537.25
Contingent Liabilities	--	363.79	0.64	98.41	64.29

	Brawn Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Cash From Operating Activities	0.05	659.75	432.37	65.36	1,065.01
Cash Flow from Investing Activities	-0.24	-71.34	-334.73	30.80	-79.97
Cash from Financing Activities	0.00	-205.34	-38.32	-65.59	-881.32
Net Cash Inflow / Outflow	-0.20	383.07	59.32	30.57	103.72

	Brawn Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
ROCE (%)	-42.59	26.21	26.22	21.29	13.59
ROE (%)	21.33	19.16	19.73	20.76	18.75
ROA (%)	4.15	14.95	18.69	9.67	9.26
EBIT Margin (%)	-3.35	34.40	31.41	8.74	26.58
Net Margin (%)	4.83	26.88	28.10	6.90	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Brawn Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Revenue Growth (%)	-7.77	10.69	15.01	31.10	9.59
EBIT Growth (%)	-358.48	24.14	18.45	-12.99	16.84
Net Profit Growth (%)	12.30	-9.09	19.61	-7.49	62.68
EPS Growth (%)	12.30	14.40	17.73	-18.33	67.41
Book Value Growth (%)	-33.62	17.30	23.77	7.70	10.19

	Brawn Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Price / Earnings	8.04	28.13	29.04	102.59	27.55
Price / Book Value	1.54	4.92	5.13	19.69	4.49
Dividend Yield (%)	0.00	1.58	0.16	0.51	0.55
EV/EBITDA	-14.63	19.75	23.13	75.50	17.88
Market Cap (₹ Cr)	4.88	18,318.10	15,219.80	21,515.93	19,292.77

	Brawn Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debt to Equity	0.00	0.00	0.00	0.00	0.24
Short term debt to equity ratio	--	0.00	0.00	--	0.14
Current Ratio	1.13	6.06	6.70	1.77	0.74
Quick Ratio	0.47	5.31	5.59	0.73	0.53
Interest Coverage	-19.50	130.11	959.59	40.90	4.45

	Brawn Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debtors to sales (%)	20.56	7.07	36.10	8.79	21.07
Asset Turnover	0.83	0.52	0.63	1.39	0.45
Receivable days	98.89	29.10	110.70	35.81	54.07
Inventory Days	223.41	69.53	65.86	82.25	32.16
Payable days	212.83	76.77	105.88	124.39	140.91
Cash Conversion Cycle	109.48	21.86	70.68	-6.33	-54.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.